{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-015210","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.405755+00:00","generated_at":"2026-06-02T09:35:51.286827+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zevra Q1 net loss $16.6M; OLPRUVA launch with 4 patients, cash runway into 2026","bullets":["Net loss of $16.6M ($0.40 loss per share) compared to $13.2M loss in Q1 2023.","Revenue $3.4M, including $2.2M French arimoclomol EAP reimbursement and $1.2M AZSTARYS royalties.","OLPRUVA commercial launch: 4 patient enrollments, ~75% covered lives as of May 1, 2024.","Arimoclomol NDA PDUFA date set for September 21, 2024; KP1077 positive Phase 2 IH data.","Debt refinancing with up to $100M; $60M drawn, net $14M added to cash; runway extends into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-015210","json":"https://secwatch.observer/filing/0001437749-24-015210.json","markdown":"https://secwatch.observer/filing/0001437749-24-015210.md","text":"https://secwatch.observer/filing/0001437749-24-015210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924015210/0001437749-24-015210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924015210/zvra20240403_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:35:51.286827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"057cf09c7eadfa3f853010bc8b47b1e2214eb711","claim":"ZEVRA THERAPEUTICS, INC. reported first quarter ended March 31, 2024 results: revenue $3.4 million, net income ($16.6) million, EPS ($0.40) per basic and diluted share.","evidence_excerpt":"patients currently enrolled and to preserve the value of the program while conducting our portfolio review. Overview of Q1 2024 Financial Results: Net revenue for Q1 2024 was $3.4 million, compared to net revenue of $3.2 million in Q1 2023. The components of revenue during the first quarter included $2.2 million in net reimbursements from the French EAP for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924015210/0001437749-24-015210-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$3.4 million"},{"label":"Net income","value":"($16.6) million"},{"label":"EPS","value":"($0.40) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}